Suspension of trading
Exscientia plc Stock
Stocks
EXAI
US30223G1022
Biotechnology & Medical Research
|
Delayed
Nasdaq
00:00:00 20/11/2024 +03
|
5-day change | 1st Jan Change | ||
| 4.840 USD | +3.20% |
|
-.--% | - |
| 21/11/24 | Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index | CI |
| 20/11/24 | Recursion Pharmaceuticals, Exscientia Complete Business Combination | MT |
| Market Cap | 500M 661M 590M 550M 941M 63.98B 950M 6.59B 2.56B 32.63B 2.48B 2.43B 104B | P/E 2022 |
-4.55x | P/E 2023 | -4.28x |
|---|---|---|---|---|---|
| Enterprise Value | 156M 206M 184M 171M 293M 19.93B 296M 2.05B 798M 10.16B 773M 757M 32.51B | EV / Sales 2022 |
1.9x | EV / Sales 2023 | 14.2x |
| Free-Float |
36.87% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +3.20% |
| 3 years | 3.8 |  | 7.91 |
| 5 years | 3.8 | | 25.16 |
| 10 years | 3.8 | | 30.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 61 | 06/06/2024 | |
| Chief Tech/Sci/R&D Officer | - | 01/05/2022 | |
John Overington
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Mario Polywka
BRD | Director/Board Member | 63 | 28/09/2017 |
Robert Ghenchev
BRD | Director/Board Member | 43 | 01/05/2020 |
Elizabeth Crain
CHM | Chairman | 61 | 12/02/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.20% | -.--% | -.--% | +4.09% | 633M | |
| -3.19% | -3.19% | +44.60% | +87.98% | 74.68B | |
| -15.86% | -16.67% | +3.92% | +50.90% | 58.7B | |
| -2.39% | -2.05% | +4.29% | +31.33% | 48.36B | |
| -6.35% | -8.35% | +303.95% | +651.28% | 43.05B | |
| +0.30% | -3.71% | +28.89% | +30.33% | 42.48B | |
| -3.82% | -4.32% | +2.49% | +101.36% | 41.39B | |
| -2.13% | +1.07% | +7.51% | +50.31% | 31.29B | |
| -3.35% | -6.35% | -13.20% | -17.22% | 23.93B | |
| -1.24% | -11.97% | -38.10% | +311.13% | 22.22B | |
| Average | -3.48% | -2.37% | +34.44% | +130.15% | 38.67B | |
| Weighted average by Cap. | -4.85% | -1.88% | +44.63% | +136.20% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 27.22M 36.01M 32.11M 29.94M 51.22M 3.48B 51.74M 359M 140M 1.78B 135M 132M 5.68B | 20.08M 26.56M 23.68M 22.08M 37.78M 2.57B 38.16M 265M 103M 1.31B 99.62M 97.56M 4.19B |
| Net income | -119M -157M -140M -131M -223M -15.2B -226M -1.57B -609M -7.75B -589M -577M -24.79B | -146M -193M -172M -161M -275M -18.68B -277M -1.93B -748M -9.53B -724M -709M -30.48B |
| Net Debt | -492M -651M -580M -541M -926M -62.97B -935M -6.49B -2.52B -32.11B -2.44B -2.39B -103B | -344M -455M -406M -378M -648M -44.05B -654M -4.54B -1.76B -22.46B -1.71B -1.67B -71.86B |
Employees
483
- Stock Market
- Stocks
- EXAI Stock
Select your edition
All financial news and data tailored to specific country editions
